(2R)-3-(tert-butoxycarbonyl)-2-isobutyl-5-hexenoic acid | 184489-29-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R)-3-(tert-butoxycarbonyl)-2-isobutyl-5-hexenoic acid
• 英文别名: 3R,S-Allyl-2R-isobutyl-butan-1,4-dioic acid-4-tert-butyl ester；3R,S-Allyl-2R-isobutyl-succinic acid-4-tert-butyl ester；2(R)-[1(RS)-(tert-butoxycarbonyl)-3-butenyl]-4-methylvaleric acid；(2R)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)hex-5-enoic acid
• CAS: 184489-29-0
• 化学式: C₁₅H₂₆O₄
• 分子量: 270.369
• InChiKey: XPLYHCXPMSYODR-PIJUOVFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R)-3-(tert-butoxycarbonyl)-2-isobutyl-5-hexenoic acid 在 palladium on activated charcoal N-甲基吗啉 、 lithium hydroxide 、 9-borabicyclo[3.3.1]nonane dimer 、 氢气 、 potassium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 21.33h， 生成 (8S,11R,12S)-11-Isobutyl-3-methyl-2,10-dioxo-1-oxa-3,9-diaza-cyclopentadecane-8,12-dicarboxylic acid 12-(benzyloxy-amide) 8-methylamide
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo

  摘要：

  To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the PI and P2 ' residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1-P2 ' linkers. With an N-methylamide at P3 ', the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-alpha release from LPS-stimulated human whole blood. Further elaboration in the P3 ' -P4 ' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of less than or equal to 0.2 muM in whole blood assay (WBA). Although the P3 ' area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3 ' was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3 ', an N-methylamide at P4 ' provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 muM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4 ' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC50 = 0.067 muM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K-i values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.

  DOI：

  10.1021/jm010127e
• 作为产物：
  描述：

  (R)-2-(2-(叔丁氧基)-2-氧代乙基)-4-甲基戊酸 、 alkaline earth salt of/the/ methylsulfuric acid 在 N,N-二甲基丙烯基脲 、 lithium iodide 、 lithium diisopropyl amide 作用下， 生成 (2R)-3-(tert-butoxycarbonyl)-2-isobutyl-5-hexenoic acid
  参考文献：
  名称：

  一系列大环MMP抑制剂的设计，合成和构效关系。

  摘要：

  设计，合成并评估了一系列掺入大环的琥珀酸酯衍生的异羟肟酸，并将其评估为基质金属蛋白酶的抑制剂。抑制剂是根据已公布的与人嗜中性粒细胞胶原酶（MMP-8）结合的巴马司他（1）的X射线晶体结构设计的。合成的化合物显示出可在体外以低纳摩尔浓度抑制选定的MMP。

  DOI：

  10.1016/s0960-894x(98)00396-5

文献信息

• Metalloproteinase inhibitors
  申请人：British Biotech Pharmaceuticals Limited

  公开号：US05866717A1

  公开（公告）日：1999-02-02

  Compounds of general formula (I), principally characterized in that R4 is a polyether group, are water soluble matrix metalloproteinase inhibitors. ##STR1##

  通式（I）的化合物主要特征在于R4是聚醚基团，是水溶性基质金属蛋白酶抑制剂。
• Compounds as inhibitor of tumor necrosis factor alpha release
  申请人：Hoffmann-La Roche Inc.

  公开号：US06239151B1

  公开（公告）日：2001-05-29

  The invention provides hydrazine derivatives of the formula wherein R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is an acyl group derived from an &agr;-, &bgr;-, &ggr;- or &dgr;-(amino, hydroxy or thiol)carboxylic acid in which the amino, hydroxy or thiol group is optionally lower alkylated or the amino group is optionally acylated, sulphonylated or amidated and in which any functional group present in a side-chain is optionally protected, or a group of the formula Het(CH2)mCO; R3 is hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl-lower alkenyl, aryl or heterocyclyl; R4 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula X-aryl, X-heteroaryl or —(CH2)n—CH═CR5R6; R5 and R6 together are lower alkylene in which one CH2 group is optionally replaced by a hetero atom; Het is heterocyclyl; X is a spacer group; m is 0, 1, 2, 3 or 4; and n is 1 or 2; and their pharmaceutically acceptable salts inhibit the release of tumour necrosis factor alpha (TNF-&agr;) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumours, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.

  本发明提供了式中R1为低碳基，低烯基，低环烷基，低环烷基-低碳基，芳基或芳基-低碳基的肼衍生物；R2是来自α-，β-，γ-或δ-（氨基，羟基或硫醇）羧酸的酰基，其中氨基，羟基或硫醇基可选择性地低碳基化或氨基基可选择性地酰化，磺化或酰胺化，并且侧链中存在的任何功能性基团可选择性地保护，或者是式Het（CH2）mCO的基团；R3是氢，低碳基，卤代低碳基，氰基-低碳基，氨基-低碳基，羟基-低碳基，低烷氧基-低碳基，低烷氧羰基-低碳基，低环烷基-低碳基，芳基-低碳基，杂环烷基-低碳基，杂环烷基羰基-低碳基，低烯基，低炔基，低环烷基，芳基-低烯基，芳基或杂环烷基；R4是低碳基，低烯基，低环烷基，低环烷基-低碳基或式X-芳基，X-杂环芳基或-（CH2）n-CHCR5R6的基团；R5和R6在一起是低碳基亚烷基，其中一个CH2基团可选择性地被杂原子替换；Het是杂环烷基；X是间隔基团；m为0,1,2,3或4；n为1或2。这些药物和它们的药物可接受的盐抑制细胞释放肿瘤坏死因子α（TNF-α）。它们可用作药物，特别是用于治疗炎症和自身免疫性疾病，骨关节炎，呼吸系统疾病，肿瘤，消瘦，心血管疾病，发热，出血和败血症。
• Design and synthesis of conformationally-constrained MMP inhibitors
  作者：Michael G. Natchus、Menyan Cheng、Christopher T. Wahl、Stanislaw Pikul、Neil G. Almstead、Rimma S. Bradley、Yetunde O. Taiwo、Glen E. Mieling、C.Michelle Dunaway、Catherine E. Snider、John M. McIver、Bobby L. Barnett、Sara J. McPhail、Melanie B. Anastasio、Biswanath De

  DOI：10.1016/s0960-894x(98)00370-9

  日期：1998.8

  A novel series of conformationally constrained matrix metalloprotease inhibitors was identified. The potencies observed for these inhibitors were highly dependent upon the substitution pattern on the caprolactam ring as well as the succinate moiety. (C) 1998 Elsevier Science Ltd. All rights reserved.
• HYDRAZINE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0993442B1

  公开（公告）日：2003-04-23
• US6239151B1
  申请人：——

  公开号：US6239151B1

  公开（公告）日：2001-05-29